Insmed, Inc. (NASDAQ:INSM) is Emerald Advisers LLC's 4th Largest Position

Emerald Advisers LLC reduced its stake in Insmed, Inc. (NASDAQ:INSM - Free Report) by 13.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 594,013 shares of the biopharmaceutical company's stock after selling 90,623 shares during the period. Insmed makes up about 2.0% of Emerald Advisers LLC's holdings, making the stock its 4th largest holding. Emerald Advisers LLC owned about 0.33% of Insmed worth $45,317,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently bought and sold shares of INSM. Elequin Capital LP purchased a new stake in Insmed during the fourth quarter worth $28,000. Steward Partners Investment Advisory LLC grew its stake in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 163 shares in the last quarter. NBC Securities Inc. acquired a new stake in shares of Insmed in the first quarter valued at about $49,000. Versant Capital Management Inc grew its stake in shares of Insmed by 546.3% in the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 590 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in shares of Insmed by 62.0% in the first quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 386 shares in the last quarter.

Insmed Stock Performance

Shares of INSM stock traded up $2.57 during trading on Monday, reaching $100.75. 664,489 shares of the company's stock traded hands, compared to its average volume of 2,276,457. The firm's 50-day moving average is $83.40 and its 200 day moving average is $77.44. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. The company has a market capitalization of $19.11 billion, a P/E ratio of -16.93 and a beta of 0.90. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $106.83.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing analysts' consensus estimates of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to the consensus estimate of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. The business's revenue was up 22.9% on a year-over-year basis. During the same period last year, the company posted ($1.06) EPS. Equities research analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Buying and Selling at Insmed

In other news, Director David W. J. Mcgirr sold 3,000 shares of the stock in a transaction on Wednesday, June 4th. The shares were sold at an average price of $73.27, for a total value of $219,810.00. Following the transaction, the director owned 97,723 shares of the company's stock, valued at $7,160,164.21. This represents a 2.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider directly owned 89,407 shares in the company, valued at $8,352,401.94. The trade was a 52.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 546,516 shares of company stock worth $48,737,083 in the last ninety days. Insiders own 3.00% of the company's stock.

Wall Street Analysts Forecast Growth

INSM has been the topic of several research analyst reports. Citigroup upgraded Insmed to a "buy" rating in a research report on Tuesday, June 10th. Leerink Partners lifted their price objective on Insmed from $100.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, June 10th. Mizuho lifted their price objective on Insmed from $96.00 to $110.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. Wells Fargo & Company lifted their price objective on Insmed from $107.00 to $119.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. Finally, HC Wainwright lifted their price objective on Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, June 11th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company's stock. According to data from MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and a consensus price target of $108.07.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.